Prognosis
GSK Raises Outlook, Looks to New Medicines to Fuel Growth
- Drugmaker sees earnings per share rising as much as 17%
- GSK is launching vaccine to protect older adults from RSV
This article is for subscribers only.
GSK Plc raised its guidance for the year after a strong start to 2023 as it prepares to begin selling one of the first vaccines to prevent a common respiratory virus.
Sales will increase by as much as 10% and earnings per share by as much as 17% this year, the UK drugmaker said in a statement Wednesday. The stock showed little change in London trading as analysts had anticipated the outlook upgrade.